Medicaid drug pricing exemption quietly handed to pharma giants
H.R. 7871 — MVP Act · Filed by Brett Guthrie (R-KY) · 17 cosponsors · Introduced Mar 9, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends Medicaid drug pricing rules to allow pharmaceutical manufacturers to offer 'value-based purchasing arrangements'—deals where payment is tied to whether patients achieve specific health outcomes—and exempts these arrangements from certain federal pricing and anti-kickback rules. Manufacturers can now report multiple prices for the same drug depending on the outcome achieved, and states can negotiate these outcome-based deals directly with drug makers. The bill benefits pharmaceutical companies by creating pricing flexibility and exempting them from standard rebate calculations, while states gain negotiating options but face complexity in administering these arrangements.
Why we flagged it
The bill's operative mechanism is to exempt value-based purchasing arrangements from standard Medicaid drug rebate calculations and anti-kickback rules, creating pricing flexibility that benefits manufacturers. The framing as 'patient access' and 'outcomes-based' obscures that the primary beneficiary is the pharmaceutical industry, which gains exemptions from price-reporting and rebate obligations.
What the text implies
- The 'multiple best price points' provision allows manufacturers to report different prices for the same drug based on outcome achievement, fragmenting the Medicaid rebate baseline and potentially raising effective prices for non-participating states and patients who don't qualify for outcome-based deals.
- The anti-kickback exception (Section 5) permits manufacturers to pay states when patients 'fail to achieve outcomes'—creating a perverse incentive for states to enroll patients least likely to succeed, shifting financial risk to Medicaid rather than manufacturers.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical manufacturers (BMY, PFE, JNJ, GH, DVA); specialty drug makers offering rare disease and gene therapies; manufacturers of inhalation, infusion, and injectable drugs